CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
about
Klotho, stem cells, and agingTargeting CDK6 in cancer: State of the art and new insightsThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisSmall molecule compounds that induce cellular senescenceSustained proliferation in cancer: Mechanisms and novel therapeutic targetsRapamycin induces pluripotent genes associated with avoidance of replicative senescenceContact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence programLongitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.The long non-coding RNA LOC441204 enhances cell growth in human glioma.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.Proteome-wide analysis reveals an age-associated cellular phenotype of in situ aged human fibroblasts.Gerosuppression in confluent cells.Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.Fasting levels of hepatic p-S6 are increased in old miceInhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitorsThe CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.Rejuvenating immunity: "anti-aging drug today" eight years later.Koschei the immortal and anti-aging drugsInsulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma.A Member of the Nuclear Receptor Superfamily, Designated as NR2F2, Supports the Self-Renewal Capacity and Pluripotency of Human Bone Marrow-Derived Mesenchymal Stem Cells.Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinomaAging is not programmed: genetic pseudo-program is a shadow of developmental growth.Gerosuppression by pan-mTOR inhibitors.MDM2 and CDK4 amplifications are rare events in salivary duct carcinomasBafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD/SCID mice.Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis.Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.USP21 promotes cell proliferation and metastasis through suppressing EZH2 ubiquitination in bladder carcinoma.Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma.Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress.CDK4/6 inhibition is more active against the glioblastoma proneural subtype.Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6ZBP-89 function in colonic stem cells and during butyrate-induced senescence.
P2860
Q26783185-CBBE30E0-4946-4AB7-BA68-F9C17F91CA46Q26796499-1089A6CC-8B5F-49CD-91CF-3677B2E4B5D5Q26865888-F936C7DC-3B30-48F5-923B-209A32975D91Q28068732-E0258665-F625-4B29-ACC1-E8EE70BD06BAQ28396388-10498754-28AD-47E3-AB3F-241B87883515Q28572137-5ED8449B-5FA0-4906-AA9D-1B7EC26169ABQ28972583-3506CA06-DF63-4C33-8E17-F0B25306516FQ30665952-5170C7B6-4C98-496C-88C6-151A58614E78Q33912230-0D8C4D21-D41C-4DE1-A4EF-774783440B20Q34227791-E989AD86-F22E-4988-9AA4-064A912265C6Q34585764-5124504E-2D03-4D65-BD60-0D66B50DEDD5Q34982499-B5543734-6B04-49E9-9894-EBC23481D4B2Q35149607-0FD10457-D083-41A3-ADB7-4D832BBFCC63Q35659675-60C45CB5-2BB3-4216-B91B-39ECABA6822EQ35869498-5D3295CE-DFFD-4F98-B1A8-1F04450CFDFCQ36182265-9FB3AE78-7C09-4E94-958D-6573C588F53AQ36187896-5A244BC1-8608-4819-BF1E-A36FA3709B51Q36188773-ABCD4FB2-52E6-47C3-89B7-5AB74620646AQ36189481-D2CD4DA3-A696-428D-987F-6C5FEAD2FDE2Q36260537-F1095B92-0181-4B84-8D00-DBC88D1EA68DQ36292001-FB861F14-2775-46CD-B53A-2F74EFAC69A3Q36375970-47C3990A-ADAD-468C-81A7-F9335B92DE28Q36405328-DC31C557-A588-4DB2-AA4B-E3313DA839C3Q36414149-8E00AF13-6BFB-4F7A-B9F6-CF3AFB77B7CCQ37046726-96A6069F-46A5-477C-92BA-DB8194B1855DQ37525814-D4F5482B-D0B8-49E8-8C47-FDBCBDEB2B41Q37610218-20537443-BA73-4C5F-9BC9-A7710BF6A247Q37688930-9361AA57-5542-482A-98BE-95B436BAE1A1Q37705958-0DB8950B-0D97-4947-9FE0-649BD4A06ABDQ38826343-1F6D9917-F4FF-4124-9A5D-B7101F027C57Q38908051-859CF2EC-78DC-4819-8E23-01C0744F6C43Q38949135-04BC4598-EDE0-4054-B9AF-7412C06DB74FQ38997891-01062232-5942-419B-AB0A-8B099F9C278BQ41002619-C455F8EB-04CA-4D15-B375-D30D89B1AC67Q41449149-7F7F1428-FF1E-4936-AD5A-A6B5AF450402Q41548769-F6A14022-FF9A-4D19-9AE2-9119BD1134F4Q41614453-A5EA0244-D8E5-4DFC-B3AA-BA7265C1F182Q42070222-5529DCB4-3FD7-4A9E-859A-B8EC1EF48DBAQ42775668-F466A51C-9A03-4438-AA41-F9FDBD98918AQ47098252-1C3F6993-B6E8-4B9F-86A2-BC603BE9C286
P2860
CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CDK4/6-inhibiting drug substit ...... vity determine geroconversion.
@en
CDK4/6-inhibiting drug substit ...... vity determine geroconversion.
@nl
type
label
CDK4/6-inhibiting drug substit ...... vity determine geroconversion.
@en
CDK4/6-inhibiting drug substit ...... vity determine geroconversion.
@nl
prefLabel
CDK4/6-inhibiting drug substit ...... vity determine geroconversion.
@en
CDK4/6-inhibiting drug substit ...... vity determine geroconversion.
@nl
P2860
P356
P1433
P1476
CDK4/6-inhibiting drug substit ...... vity determine geroconversion.
@en
P2093
Olga V Leontieva
P2860
P304
P356
10.4161/CC.26130
P577
2013-08-22T00:00:00Z